TeraRecon Launches Updated Intuition 4.10 Cardiac MRI Software
The updated software reportedly provides access to more than 200 enhanced features including optimized hanging protocols with a cardiac MRI viewer and perfusion quantification analysis.
Offering a range of enhanced features to facilitate precision with cardiac magnetic resonance imaging (MRI), TeraRecon has launched an updated version of its software-as-a-service (SaaS) platform Intuition 4.10.
In addition to facilitating expedited measurements and reporting on cardiac MRI cases, the Intuition 4.10 software provides a dedicated cardiac MRI viewer with hanging protocols and over 200 enhanced features, according to TeraRecon.
The updated software-as-a-service (SaaS) platform Intuition 4.10 from TeraRecon reportedly offers more than 200 enhanced features for cardiac MRI assessment and workflow. (Images courtesy of Adobe Stock.)
The company added that features such as extracellular volume (ECV) mapping, 2D flow analysis and a new global strain analysis workflow provide significant quantification tools for cardiac MRI analysis.
"TeraRecon's Intuition 4.10 release includes significant new enhancements to cardiac MR workflows," noted Christopher Maroules, M.D., the chief of cardiothoracic imaging at the Naval Medical Center Portsmouth in Portsmouth, Va. “This release allows me to start standardizing my post-processing cardiac workflows onto a single, broad tool for imaging workflows. The versatility of the dedicated cardiac MR viewer and various cardiac MR workflows enable me to conduct my day-to-day cardiac MR analysis in a streamlined and consistent manner."
Can Abbreviated Breast MRI Have an Impact in Assessing Post-Neoadjuvant Chemotherapy Response?
April 24th 2025New research presented at the Society for Breast Imaging (SBI) conference suggests that abbreviated MRI is comparable to full MRI in assessing pathologic complete response to neoadjuvant chemotherapy for breast cancer.
New bpMRI Study Suggests AI Offers Comparable Results to Radiologists for PCa Detection
April 15th 2025Demonstrating no significant difference with radiologist detection of clinically significant prostate cancer (csPCa), a biparametric MRI-based AI model provided an 88.4 percent sensitivity rate in a recent study.
Could Ultrafast MRI Enhance Detection of Malignant Foci for Breast Cancer?
April 10th 2025In a new study involving over 120 women, nearly two-thirds of whom had a family history of breast cancer, ultrafast MRI findings revealed a 5 percent increase in malignancy risk for each second increase in the difference between lesion and background parenchymal enhancement (BPE) time to enhancement (TTE).
